Frances Hull
Family · Yakima, WANPI 1336531870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,678, 6.5 times the $257 reported in 2021. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$902
- Pfizer$571
- Novo Nordisk$387
- GSK$358
- Otsuka America Pharmaceutical, Inc.$269
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 38 | $1,240 |
| AbbVie | 65 | $902 |
| Pfizer | 45 | $571 |
| Novo Nordisk | 32 | $387 |
| GSK | 14 | $358 |
| Otsuka America Pharmaceutical, Inc. | 4 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $221 |
| Boehringer Ingelheim | 9 | $212 |
| Xeris Pharmaceuticals, Inc. | 10 | $201 |
| Astellas Pharma US Inc | 7 | $171 |
| Neurocrine Biosciences, Inc. | 2 | $122 |
| Sanofi-aventis U.S. LLC | 5 | $116 |
| Sumitomo Pharma America, Inc. | 5 | $111 |
| Sunovion Pharmaceuticals Inc. | 5 | $110 |
| Amgen | 5 | $74 |
| Lundbeck LLC | 4 | $69 |
| Corcept Therapeutics | 4 | $68 |
| Bayer | 4 | $56 |
| Novartis | 3 | $55 |
| Viiv Healthcare Company | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Chiesi USA, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $38 |
| Mylan Specialty L.p. | 2 | $36 |
| Johnson & Johnson | 1 | $35 |
| Exact Sciences | 2 | $35 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Urovant Sciences Inc | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Vertex | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 3 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| QOL Medical, LLC | 1 | $13 |
| Morphosys, US Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,842 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 66 | $77,430 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $77,240 |
| OzempicSemaglutide | 71 | $73,513 |
| EliquisApixaban | 55 | $71,583 |
| JardianceEmpagliflozin | 27 | $43,126 |
| JanuviaSitagliptin Phosphate | 15 | $24,707 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $22,866 |
| RybelsusSemaglutide | 13 | $22,505 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $20,170 |
| XareltoRivaroxaban | 14 | $16,917 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $13,548 |
| Varenicline Tartrate | 24 | $5,614 |
| Omeprazole | 275 | $5,570 |
| MyrbetriqMirabegron | 11 | $5,379 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $4,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,240 | $120,467148 claims |
| Novo NordiskOzempic, Rybelsus | $387 | $96,01884 claims |
| GSKTrelegy Ellipta | $358 | $77,24075 claims |
| PfizerEliquis | $571 | $71,58355 claims |
| Boehringer IngelheimJardiance | $212 | $43,12627 claims |
| Johnson & JohnsonXarelto | $35 | $16,91714 claims |
| Astellas Pharma US IncMyrbetriq | $171 | $5,37911 claims |
| Lilly USA, LLCHumulin 70-30 | $38 | $1,11612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Yakima
- Sarah PerlmanYakima$12K
- Tesa LinstadYakima$8K
- Melanie AdamsYakima$7K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.